LB Pharmaceuticals 2026 Stifel Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Thank you. Happy to be on this panel with Heather Turner, CEO of LB Pharmaceuticals. We'll keep it conversational, but maybe I'll just pass it over to Heather to give a quick update on the company. I know it can't be that quick because you have five programs for this drug, but you got 30 seconds, so go.
Great. Where we sit today is quite different than where we were a year ago when we went public last September. LB-102 is our asset, and it is reading out phase III schizophrenia data in the first half of next year. We'll have bipolar depression data coming in 2028, and we'll have phase II adjunctive MDD data coming in 2029. We have very meaningful data coming over the next three years, and we have cash that takes us into and beyond the second quarter of 2029. All of those trials are funded. We've also funded all of the activities related to an NDA submission with respect to schizophrenia. This includes the open-label safety trial that we need to run, as well as all the NDA-enabling studies. We're well-positioned with a successful phase III trial to put ourselves in a position to submit an NDA.
Great. Well, yeah, maybe let's talk about the upcoming schizophrenia readout. You have some very strong phase II data. There's the amisulpride data. Maybe outside of that, do you want to just talk about the study design and all the little things you've done to risk mitigation there?
The phase III NOVA-2 trial is actually quite similar in size and scope to the phase II NOVA-1 trial. It's 25 sites in the U.S. We're targeting the enrollment of 460 patients. We are evaluating two doses in our NOVA-2 trial. It's 50 and 100 milligrams, which is a little bit different than the NOVA-1. NOVA-1 had three doses, so that's one way of mitigating the placebo rate is just reducing a dose arm. The other thing that we've done is we've extended the duration. The NOVA-2 trial is six weeks in duration inpatient. The NOVA-1 trial was four weeks in duration. When we look at the efficacy curves from the NOVA-1 trial, we think there's an opportunity to see some additional separation from placebo.
The other thing we've done is we've taken a number of measures to just continue to have that frequent, consistent oversight of the sites in the trial. One thing we've done is we've created an app where we can look at our data real-time. We can see any sort of deviations or outlier information or anything like that that allows us to get on top of that data really quickly, which in these trials is really important. That's been a nice change that we've taken. We, of course, have done all of the measures we did in NOVA-1 with NOVA-2 in terms of managing that placebo rate. We have vendors that help identify and exclude professional patients. We were very deliberate in the number of scales that we chose to include in this trial.
We know that both rater fatigue and patient fatigue are real contributors to placebo rates. All of those same measures that we did in NOVA-1, we're also doing in NOVA-2.
Okay, great. Do you want to maybe just kind of frame, given we're getting close to the top line now, like beyond hitting a P-value on the PANSS and knowing you can register the drug, what else would constitute a win here and increase your confidence overall in LB-102?
One of the most, I think, attractive attributes of LB-102 in schizophrenia is the balance that it could potentially provide. We see in the COBENFY launch, for example, that you need to have not just efficacy, you also need to have a tolerability and a simplicity of use that I think will enable patients to stay on the drug. For us, I think seeing a balanced profile in the NOVA-2 trial is going to be important. We want to see that competitive efficacy. We want to see that we'll treat the patients who are experiencing positive symptoms. Equally so, we want to see a tolerability profile which would enable these patients to stay on the drug. We know that there are certain adverse events that are big contributors to discontinuation, one of which is EPS.
If we continue to see a lower rate of EPS, we think that that's very attractive. One of the other things we saw in NOVA-1 that I think will be important in NOVA-2 is, do we see an effect early? We know that seeing an effect early is something that's really attractive to prescribers. In NOVA-1, we saw an effect as early as the first week of evaluation, and so we hope that we'll continue to see that. Then, we already know this, but simplicity of use continues to be important. We have once-daily dosing. There is no titration. We don't have a food effect, and so we think that that will continue to be important.
Okay, great. On the safety side more specifically, maybe just talk about what are the AEs that you think look better and differentiated from other drugs, and where are there still any outstanding questions in your mind?
Well, the one we just talked about is EPS. EPS is an adverse event that has been associated with antipsychotics since the very first antipsychotics. The fact that we saw a very low rate of EPS despite the fact that we're a D2 antagonist, despite the fact that we have 70% dopamine receptor occupancy, is, I think, something very differentiating. We had an R&D Day at the end of October where we presented some preclinical data that we believe provides a plausible mechanism as to why we have that low rate of EPS, and that is the fact that we actually do not hit the motor striatum nearly as much as other D2 antagonists. We think that that's a potential reason to believe that we'll continue to see a low rate of EPS. I think we saw a nice treatment-emergent adverse effect profile.
We didn't see anything there that we thought was unexpected or unusual. I think we're a D2 antagonist. We know we'll see increases in prolactin. I think one of the things that we'll continue to assess is just whether it's a lab value or whether it actually results in clinical manifestation. What we saw in our NOVA-1 trial was a very low rate of adverse events associated with that, and none of them led to discontinuation. It actually isn't an adverse event that often leads to discontinuation relative to others. We'll continue to look at that, but so far, what we've seen is a very, very low rate that results in adverse events associated with that, and none of them lead to discontinuation.
What is your level of confidence that if this study's positive, you have enough data to file in schizophrenia?
We had a robust engagement with FDA at the time of our end of phase II meeting. We designed NOVA-1 to be registrational. It was 359 patients. We had all of the sensitivity analyses that you would expect for a phase III trial, including the real conservative imputation for missing data, the one that's most punitive to LB-102. Coming out of that engagement, we asked FDA whether they considered that trial to be adequate and well-controlled, and they said that it had many of the characteristics of an adequate and well-controlled trial. We're highly confident in that trial being robust and being considered an adequate and well-controlled trial. If we have an equally robust NOVA-2 trial, we think that we're in a really good position.
Great. Maybe on the commercial side in schizophrenia, obviously there's a lot of talk about other atypicals having softer launches in schizophrenia. COBENFY sold a lot worse than it surveyed, at least for what it's worth on everything maybe surveys better than it sells. Just in the context of that, how do you think about tackling that market, and what gives you the confidence that LB-102 can still be commercially successful in schizophrenia?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
